Figure 3.
Aryl hydrocarbon receptor nuclear translocator-like protein 1 (BMAL1) expression positively correlates with the mutational and neoantigen load in metastatic melanomas. (A) Spearman’s correlation between the expression of BMAL1 and the number of total mutations and predicted neoantigens in The Cancer Genome Atlas (TCGA) metastatic melanomas (n = 68). NetMHCpan-predicted neoantigens were obtained from Ref. (40). Gene expression of (B) DNA-repair programs and (C) selected base excision repair enzymes according to the expression of BMAL1 in TCGA metastatic melanomas (n = 340). Pathway scores were calculated using single sample Gene Set Enrichment Analysis available in the GSVA R package. The median expression of BMAL1 was used as the cutoff to dichotomize the population. The boxes extend from the 25th to the 75th percentile, the central bold line shows the median, and whiskers are drawn from minimum to maximum values. Comparisons were performed using the two-sided Wilcoxon–Mann–Whitney test. *Significantly different from the low BMAL1 group.
